Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24FN3O2S.C4H6O5 |
Molecular Weight | 523.574 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](CC(O)=O)C(O)=O.CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)C3=CSC(=N3)C4=CC=C(F)C=C4
InChI
InChIKey=SQXUKOJKIWCALK-AAXLQGCPSA-N
InChI=1S/C20H24FN3O2S.C4H6O5/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24;5-2(4(8)9)1-3(6)7/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25);2,5H,1H2,(H,6,7)(H,8,9)/t16-;2-/m10/s1
Molecular Formula | C20H24FN3O2S |
Molecular Weight | 389.487 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H6O5 |
Molecular Weight | 134.0874 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ibiglustat (GZ/SAR402671 or Genz-682452) is a small molecule inhibitor of glucosylceramide synthase. Ibiglustat has been demonstrated to effectively lower glycosphingolipid synthesis. Genzyme, a Sanofi Company is developing Ibiglustat for the treatment of Parkinson's Disease, Gaucher Disease, and Fabry Disease.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2063 Sources: http://adisinsight.springer.com/drugs/800036945 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
142 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
529 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2420 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
20600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
26.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32851809 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
VENGLUSTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/32851809/ |
yes | |||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02228460
A phase 2 study assessed the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of Ibiglustat (GZ/SAR402671) in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease: GZ/SAR402671 15 mg once daily orally for 26 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:55:39 GMT 2023
by
admin
on
Fri Dec 15 15:55:39 GMT 2023
|
Record UNII |
94855LQZ8D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
755820
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GH-117
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
SUB192872
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
100000177469
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
C171783
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
1629063-78-0
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
94855LQZ8D
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY | |||
|
60199241
Created by
admin on Fri Dec 15 15:55:39 GMT 2023 , Edited by admin on Fri Dec 15 15:55:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |